Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 10/20 | 0.51 |
| ▸ | SIRT1 | Q96EB6 | 7/20 | 0.51 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.48 |
| ▸ | SIRT3 | Q9NTG7 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31277511 | 1.00 | SIRT2 (0.51) | SIRT2SIRT1FOLH1SIRT3ALDH1A1 | |
| SCHEMBL16762202 | 0.93 | FOLH1 (0.52) | FOLH1 | |
| SCHEMBL16762023 | 0.90 | ALDH1A1 (0.46) | SIRT2SIRT1FOLH1ALDH1A1SMN1; SMN2 | |
| SCHEMBL21543552 | 0.90 | MAPT (0.57) | FOLH1 | |
| SCHEMBL28820442 | 0.90 | SIRT2 (0.47) | SIRT2SIRT1FOLH1SIRT3ALDH1A1 | |
| SCHEMBL21715244 | 0.89 | CA1 (0.54) | FOLH1 | |
| SCHEMBL16762298 | 0.89 | CA1 (0.54) | FOLH1 | |
| SCHEMBL28948762 | 0.88 | SIRT2 (0.47) | SIRT2SIRT1FOLH1SIRT3ALDH1A1 | |
| SCHEMBL21715232 | 0.88 | CTSL (0.55) | SIRT2SIRT1SIRT3ALDH1A1SMN1; SMN2 | |
| SCHEMBL23357782 | 0.87 | MAPT (0.54) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240189360-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE HOMING AND GRAFTING OF HEMATOPOETIC STEM CELLS | 7 HILLS PHARMA INC. (US) | 2024-06-13 | — | — | US | disclosed |
| US-11311619-B2 | Integrin activator vaccine compositions | 7 Hills Pharma Inc. and Texas Heart Institute (US) | 2022-04-26 | — | — | US | disclosed |
| EP-3104867-B1 | COMPOSITIONS AND METHODS TO IMPROVE THE HOMING AND GRAFTING OF HEMATOPOETIC STEM CELLS | 7 Hills Pharma LLC (US) | 2022-01-19 | — | — | EP | disclosed |
| US-20210023207-A1 | NOVEL INTEGRIN ACTIVATOR VACCINE COMPOSITIONS | 7 Hills Pharma LLC (US) | 2021-01-28 | — | — | US | disclosed |
| US-10716849-B2 | Methods of administering novel integrin activator vaccine compositions | 7 Hills Pharma LLC (US) | 2020-07-21 | — | — | US | disclosed |
| US-10709781-B2 | Integrin activator checkpoint inhibitor compositions | 7 Hills Pharma LLC (US) | 2020-07-14 | — | — | US | disclosed |
| US-20200054743-A1 | NOVEL INTEGRIN ACTIVATOR CHECKPOINT INHIBITOR COMPOSITIONS | 7 Hills Pharma LLC (US) | 2020-02-20 | — | — | US | disclosed |
| US-20190343952-A1 | METHODS OF ADMINISTERING NOVEL INTEGRIN ACTIVATOR VACCINE COMPOSITIONS | 7 Hills Pharma LLC (US) | 2019-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11311619-B2 | Integrin activator vaccine compositions | ITGAM, ITGA2B, ITGA1 | SIRT2 1024/4885SIRT1 818/4885FOLH1 3309/4885 |
| US-20200054743-A1 | NOVEL INTEGRIN ACTIVATOR CHECKPOINT INHIBITOR COMPOSITIONS | CD47, ITGA1, ITGA2B | SIRT2 1133/4885SIRT1 743/4885FOLH1 2727/4885 |
| US-10709781-B2 | Integrin activator checkpoint inhibitor compositions | CD47, ITGA1, ITGAM | SIRT2 998/4885SIRT1 609/4885FOLH1 2769/4885 |
| US-10716849-B2 | Methods of administering novel integrin activator vaccine compositions | ITGAM, ITGA2B, ITGA2 | SIRT2 1130/4885SIRT1 980/4885FOLH1 1822/4885 |
| US-20190343952-A1 | METHODS OF ADMINISTERING NOVEL INTEGRIN ACTIVATOR VACCINE COMPOSITIONS | ITGAM, ITGA2B, ITGA2 | SIRT2 1130/4885SIRT1 980/4885FOLH1 1822/4885 |
| US-20210023207-A1 | NOVEL INTEGRIN ACTIVATOR VACCINE COMPOSITIONS | ITGA2B, ITGAM, ITGAV | SIRT2 985/4885SIRT1 820/4885FOLH1 2843/4885 |
| US-20240189360-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE HOMING AND GRAFTING OF HEMATOPOETIC STEM CELLS | CXCL12, ITGB3, ITGB7 | SIRT2 4264/4885SIRT1 3379/4885FOLH1 2748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.